Skip to main content
. 2023 Oct 26;14:1249462. doi: 10.3389/fimmu.2023.1249462

Figure 3.

Figure 3

The proportion of patients being infected by SARS-CoV-2 in the study groups. Patients treated with AZD7442 as pre-exposure prophylaxis are represented as a red line, and patients who were not treated with AZD7442 are represented as a blue line. Patients who were infected in the three months preceding the enrolment are separately analysed and represented as a black line.